Kymera Therapeutics (NASDAQ:KYMR) CFO Sells 77,109 Shares of Stock

Posted by on Jul 2nd, 2026

Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) CFO Bruce Jacobs sold 77,109 shares of the firm’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $114.96, for a total transaction of $8,864,450.64. Following the transaction, the chief financial officer directly owned 244,883 shares of the company’s stock, valued at $28,151,749.68. This represents a 23.95% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Kymera Therapeutics Trading Down 0.6%

Shares of KYMR stock traded down $0.69 during trading hours on Thursday, hitting $113.51. The company’s stock had a trading volume of 788,284 shares, compared to its average volume of 767,552. The company has a 50 day moving average of $86.36 and a 200 day moving average of $82.74. The stock has a market cap of $9.34 billion, a PE ratio of -31.80 and a beta of 1.95. Kymera Therapeutics, Inc. has a 12-month low of $36.65 and a 12-month high of $130.05.

Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) last issued its earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.18. The firm had revenue of $34.37 million during the quarter, compared to analysts’ expectations of $8.27 million. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The firm’s revenue was up 55.5% compared to the same quarter last year. During the same quarter last year, the company posted ($0.82) earnings per share. As a group, analysts anticipate that Kymera Therapeutics, Inc. will post -3.28 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on KYMR. Loop Capital set a $97.00 price objective on Kymera Therapeutics in a report on Monday, June 8th. Brookline Capital Markets reaffirmed a “buy” rating on shares of Kymera Therapeutics in a report on Monday, June 8th. Morgan Stanley reiterated an “overweight” rating and set a $119.00 price target on shares of Kymera Therapeutics in a research report on Thursday, April 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Tuesday, April 21st. Finally, Jefferies Financial Group began coverage on shares of Kymera Therapeutics in a research note on Monday, March 16th. They set a “buy” rating and a $110.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $121.41.

Read Our Latest Report on KYMR

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Baker BROS. Advisors LP raised its position in shares of Kymera Therapeutics by 30.2% in the fourth quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock valued at $673,620,000 after buying an additional 2,005,813 shares during the last quarter. Avoro Capital Advisors LLC boosted its position in Kymera Therapeutics by 17.7% during the fourth quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock worth $581,610,000 after acquiring an additional 1,124,747 shares during the last quarter. Vanguard Group Inc. grew its stake in Kymera Therapeutics by 15.6% during the 4th quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock valued at $487,685,000 after acquiring an additional 845,922 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Kymera Therapeutics by 20.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock valued at $479,258,000 after acquiring an additional 1,061,957 shares during the last quarter. Finally, State Street Corp boosted its holdings in shares of Kymera Therapeutics by 9.4% during the 4th quarter. State Street Corp now owns 2,209,837 shares of the company’s stock worth $171,947,000 after purchasing an additional 190,383 shares during the last quarter.

Kymera Therapeutics Company Profile

(Get Free Report)

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.

Featured Stories

Insider Buying and Selling by Quarter for Kymera Therapeutics (NASDAQ:KYMR)

Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.